Adrikaas is a Ready-To-Use formulation of Doxorubicin Hydrochloride, an anthracycline cytotoxic agent used in a wide range of cancer treatments. It offers convenience, precision, and reduced preparation time, making it ideal for clinical oncology settings.

Available Strengths:

• Adrikaas 10 mg

• Adrikaas 50 mg

Therapeutic Indications:

• Breast Cancer

• Ovarian Cancer

• Lung Cancer

• Lymphomas

• Leukemias

• Bladder Cancer

• Soft Tissue Sarcomas

Mechanism of Action:
Doxorubicin intercalates into DNA, inhibits topoisomerase II, and generates free radicals that damage cellular membranes, DNA, and proteins—leading to cancer cell apoptosis.

Key Features:

• Ready-to-use formulation – no reconstitution required

• Enhances safety, accuracy, and efficiency in hospital settings

• GMP-certified manufacturing for global quality standards

• Reduces risk of handling errors and contamination

• Available in sterile, prefilled vials

Packaging:

• Sterile solution in glass vials, ready for intravenous administration

Storage:
Store at 2°C to 8°C. Do not freeze. Protect from light.

Note: For intravenous use only. Administer under the supervision of qualified healthcare professionals.